BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/7/2026 9:40:18 AM | Browse: 1 | Download: 0
 |
Received |
|
2026-02-24 01:13 |
|
Peer-Review Started |
|
2026-02-24 01:14 |
|
First Decision by Editorial Office Director |
|
2026-02-27 08:47 |
|
Return for Revision |
|
2026-02-27 08:47 |
|
Revised |
|
2026-03-09 12:13 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-05-06 03:20 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-05-06 05:44 |
|
Articles in Press |
|
2026-05-06 05:44 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-29 04:11 |
|
Publish the Manuscript Online |
|
2026-08-07 09:40 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Opinion Review |
| Article Title |
C-reactive protein/albumin ratio in immunochemotherapy for advanced gastric cancer: Prognostic value, clinical challenges, and future directions
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yan-Song Hou, Ze-Yuan Yu and Xiao-Jun Yang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xiao-Jun Yang, Associate Professor, Chief Physician, MD, Department of Hepatobiliary Surgery, Gansu Provincial Hospital, No. 199 Donggang West Road, Chengguan District, Lanzhou 730000, Gansu Province, China. yangxjmd@aliyun.com |
| Key Words |
Gastric cancer; C-reactive protein-to-albumin ratio; Immunochemotherapy; Prognosis; Inflammation; Nutrition |
| Core Tip |
C-reactive protein/albumin ratio (CAR) has attracted attention because it is easy to obtain, highly reproducible in clinical practice, and biologically linked to systemic inflammation, malnutrition, cachexia, treatment tolerance, and immune competence. We argue that, in Immunochemotherapy for advanced gastric cancer, the greatest value of CAR is not as an independent determinant of treatment selection, but as a complementary host-state biomarker that should be interpreted alongside programmed death ligand 1, mismatch repair status, metastatic burden, and performance status. The field now needs prospective validation, dynamic monitoring of CAR, and clinical trials testing whether CAR-guided nutritional or anti-inflammatory interventions can improve clinically meaningful outcomes. |
| Publish Date |
2026-08-07 09:40 |
| Citation |
Hou YS, Yu ZY, Yang XJ. C-reactive protein/albumin ratio in immunochemotherapy for advanced gastric cancer: Prognostic value, clinical challenges, and future directions. World J Gastrointest Oncol 2026; 18(8): 120245
|
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i8/120245.htm |
| DOI |
https://doi.org/10.4251/wjgo.v18.i8.120245 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
